Loading
CHRNA4 (Neuronal acetylcholine receptor subunit alpha-4) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer.
Component of neuronal acetylcholine receptors (nAChRs) that function as pentameric, ligand-gated cation channels with high calcium permeability among other activities. nAChRs are excitatory neurotrasnmitter receptors formed by a collection of nAChR subunits known to mediate synaptic transmission in the nervous system and the neuromuscular junction. Each nAchR subunit confers differential attributes to channel properties, including activation, deactivation and desensitisation kinetics, pH sensitivity, cation permeability, and binding to allosteric modulators. CHRNA4 forms heteropentameric neuronal acetylcholine receptors with CHRNB2 and CHRNB4, as well as CHRNA5 and CHRNB3 as accesory subunits.
Open Targets scores its association with cancer at 0.55 (direct and indirect evidence; datatypes literature 0.68, genetic association 0.60, clinical 0.55).
In plain words · CHRNA4 (Neuronal acetylcholine receptor subunit alpha-4) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer.
CHRNA4 (Neuronal acetylcholine receptor subunit alpha-4) is a gene. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer.
Component of neuronal acetylcholine receptors (nAChRs) that function as pentameric, ligand-gated cation channels with high calcium permeability among other activities.
No product in this corpus aims at CHRNA4 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA tissue enriched, which says where the protein sits but not whether the tumour differs from normal tissue. HPA CHRNA4: RNA tissue enriched (liver 83 nTPM); no normal tissue stained high. Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Lung cancer (all types)); Open Targets associates it with 1 specific cancer type at or above 0.5 (lung cancer). (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas CHRNA4 tissue; Open Targets ENSG00000101204 associations
First described 1995. Earliest sequence paper UniProt cites for the protein: Monteggia L.M. et al, Gene, 1995, "Cloning and transient expression of genes encoding the human alpha-4 and beta-2 neuronal nicotinic acetylcholine receptor (nAChR) subunits". Source.
Sources: HGNC HGNC:1958 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P43681 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000101204 (association with cancer (MONDO_0004992) 0.55; per-cancer scores at or above 0.5: lung cancer 0.51 (GraphQL API, CC0))
Component of neuronal acetylcholine receptors (nAChRs) that function as pentameric, ligand-gated cation channels with high calcium permeability among other activities. nAChRs are excitatory neurotrasnmitter receptors formed by a collection of nAChR subunits known to mediate synaptic transmission in the nervous system and the neuromuscular junction. Each nAchR subunit confers differential attributes to channel properties, including activation, deactivation and desensitisation kinetics, pH sensitivity, cation permeability, and binding to allosteric modulators. CHRNA4 forms heteropentameric neuronal acetylcholine receptors with CHRNB2 and CHRNB4, as well as CHRNA5 and CHRNB3 as accesory subunits. Is the most abundant nAChR subtype expressed in the central nervous system. Found in two major stoichiometric forms,(CHRNA4)3:(CHRNB2)2 and (CHRNA4)2:(CHRNB2)3, the two stoichiometric forms differ in their unitary conductance, calcium permeability, ACh sensitivity and potentiation by divalent cation. Involved in the modulation of calcium-dependent signalling pathways, influences the release of neurotransmitters, including dopamine, glutamate and GABA. Location: Synaptic cell membrane; Cell membrane (UniProt). Locus 20q13.33 (HGNC).
RNA: tissue enriched (liver 83 nTPM), detected in some normal tissues.
No normal tissue stained high.
RNA cancer enhanced: Liver Hepatocellular Carcinoma 3 pTPM.
No cancer stained high; medium in breast cancer, carcinoid, cervical cancer, colorectal cancer.
HPA CHRNA4 tissue · HPA CHRNA4 pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"CHRNA4" OR ABSTRACT:"CHRNA4" OR TITLE:"cholinergic receptor nicotinic alpha 4 subunit" OR ABSTRACT:"cholinergic receptor nicotinic alpha 4 subunit" OR TITLE:"Neuronal acetylcholine receptor subunit alpha-4" OR ABSTRACT:"Neuronal acetylcholine receptor subunit alpha-4" OR TITLE:"EBN1" OR ABSTRACT:"EBN1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CHRNA4, not a curated reading list.